Ovid Therapeutics (OVID) Other Non Operating Income (2021 - 2026)
Ovid Therapeutics (OVID) posted Other Non Operating Income of $858000.0 for Q1 2026, down 96.09% on a QoQ basis from $22.0 million in Q4 2025, and down 62.94% year-over-year from $2.3 million in Q1 2025.
Ovid Therapeutics (OVID) Other Non Operating Income (2021 - 2026) Analysis & Trends
Ovid Therapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at $858000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 62.94% year-over-year to $858000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (down 26.44% YoY) and the FY2025 annual result came in at $25.0 million, down 29.41% from the prior year.
- Other Non Operating Income was $858000.0 for Q1 2026 at Ovid Therapeutics, down from $22.0 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $29.0 million in Q2 2024 and bottomed at -$780000.0 in Q3 2024.
- A 5-year average of $4.1 million and a median of $858000.0 in 2026 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 1546.15% in 2024, while the deepest fall reached 200.52% in 2024.
- Ovid Therapeutics' Other Non Operating Income stood at $668123.0 in 2022, then surged by 329.11% to $2.9 million in 2023, then sank by 48.76% to $1.5 million in 2024, then surged by 1394.69% to $22.0 million in 2025, then sank by 96.09% to $858000.0 in 2026.
- Business Quant data shows OVID's Other Non Operating Income at $858000.0 in Q1 2026, $22.0 million in Q4 2025, and $365000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Ovid Therapeutics | 121.41 Mn | -34.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | 21.96 Mn |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 389,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -780,000.00 |
| Jun 30, 2024 | 29.04 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 776,000.00 |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 668,123.00 |
| Sep 30, 2022 | 836,085.00 |
| Jun 30, 2022 | -284,127.00 |
| Mar 31, 2022 | 209,050.00 |
| Mar 31, 2021 | 500,000.00 |